Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism

Journal of Immunology

Volumn 170, Issue 9, 2003, Pages 4683-4692

  Doebele, Robert C ^a   Pashine, Achal ^a   Liu, Wendy ^a   Zaller, Dennis M ^b   Belmares, Michael ^c   Busch, Robert ^a,d   Mellins, Elizabeth D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c STANFORD UNIVERSITY   (United States)

^d KINEMED INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2; HLA ANTIGEN CLASS 2 ASSOCIATED II PEPTIDE; HLA DM ANTIGEN; HLA DR3 ANTIGEN; PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISSOCIATION; ENDOSOME; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN SYNTHESIS;

EID: 0037406723     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.9.4683     Document Type: Article

References (61)

1. McFarland, B. J., and C. Beeson. 2002. Binding interactions between peptides and proteins of the class II major histocompatibility complex. Med. Res. Rev. 22:168.
2. Rammensee, H. G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
3. Cresswell, P. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259.
4. Ghosh, P., M. Amaya, E. Mellins and D. C. Wiley. 1995. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature. 378:457.
5. Eastman, S., M. Deftos, P. C. DeRoos, D. H. Hsu, L. Teyton, N. S. Braunstein, C. J. Hackett, and A. Rudensky. 1996. A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex-specific monoclonal antibody. Eur. J. Immunol. 26:385.
6. Jasanoff, A., S. Song, A. R. Dinner, G. Wagner, and D. C. Wiley. 1999. One of two unstructured domains of Ii becomes ordered in complexes with MHC class II molecules. Immunity 10:761.
7. Nakagawa, T. Y., and A. Y. Rudensky. 1999. The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation. Immunol. Rev. 172:121.
8. Villadangos, J. A., and H. L. Ploegh. 2000. Proteolysis in MHC class II antigen presentation: who's in charge? Immunity 12:233.
9. Rabinowitz, J. D., M. Vrljic, P. M. Kasson, M. N. Liang, R. Busch, J. J. Boniface, M. M. Davis, and H. M. McConnell. 1998. Formation of a highly peptide-receptive state of class II MHC. Immunity 9:699.
10. Sette, A., S. Southwood. J. Miller, and E. Appella. 1995. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J. Exp. Med. 181:677.
11. Rudensky, A. Y., P. Preston-Hurlburt, S. C. Hong, A. Barlow, and C. A. Janeway, Jr. 1991. Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622.
12. Chicz, R. M., R. G. Urban, W. S. Lane, J. C. Gorga, L. J. Stem, D. A. Vignali, and J. L. Strominger. 1992. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358:764.
13. d. Science 256:1817.
14. Busch, R., R. C. Doebele, N. S. Patil, A. Pashine, and E. D. Mellins. 2000. Accessory molecules for MHC class II peptide loading. Curr. Opin. Immunol. 12:99.
15. Mellins, E., P. Cameron, M. Amaya, S. Goodman, D. Pious, L. Smith, and B. Arp. 1994. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides. J. Exp. Med. 179:541.
16. Riberdy, J. M., and P. Cresswell. 1992. The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation. J. Immunol. 148:2586.
17. Fung-Leung, W. P., C. D. Surh, M. Liljedahl, J. Pang, D. Leturcq, P. A. Peterson, S. R. Webb, and L. Karlsson. 1996. Antigen presentation and T cell development in H2-M-deficient mice. Science 271:1278.
18. Martin, W. D., G. G. Hicks, S. K. Mendiratta, H. I. Leva, H. E. Ruley, and L. Van Kaer. 1996. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 84: 543.
19. Miyazaki, T., P. Wolf, S. Tourne, C. Waltzinger, A. Dierich, N. Barois, H. Ploegh, C. Benoist, and D. Mathis. 1996. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 84:531.
20. + T cell maturation in BALB/c mice. J. Immunol. 166:5087.
21. Gautam, A. M., M. Yang, P. J. Milburn, R. Baker, A. Bhatnagar, J. McCluskey, and T. Boston. 1997. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner. J. Immunol. 159:2782.
22. Liang, M. N., C. Lee, Y, Xia, and H. M. McConnell. 1996. Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC. Biochemistry 35:14734.
23. van Ham, S. M., U. Gruneberg, G. Malcherek, I. Broker, A. Melms, and J. Trowsdale. 1996. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J. Exp. Med. 184:2019.
24. Weber, D. A., B. D. Evavold, and P. E. Jensen. 1996. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 274:618.
25. Kinsella, T. M., and G. P. Nolan. 1996. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum. Gene Ther. 7:1405.
26. Doebele, R. C., R. Busch, H. M. Scott, A. Pashine, and E. D. Mellins. 2000. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity 13:517.
27. Avva, R. R., and P. Cresswell. 1994. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1:763.
28. Lampson, L. A., and R. Levy. 1980. Two populations of Ia-like molecules on a human B cell line. J. Immunol. 125:293.
29. Watanabe, M., T. Suzuki, M. Taniguchi, and N. Shinohara. 1983. Monoclonal anti-Ia murine alloantibodies crossreactive with the Ia-homologues of other mammalian species including humans. Transplantation 36:712.
30. Busch, R., R. C. Doebele, E. von Scheven, J. Fahrni, and E. D. Mellins. 1998. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function. J. Immunol. 160:734.
31. Guy, K., V. Van Heyningen, B. B. Cohen, D. L. Deane, and C. M. Steel. 1982. Differential expression and serologically distinct subpopulations of human Ia antigens detected with monoclonal antibodies to Ia α and β chains. Eur. J. Immunol. 12:942.
32. Clark, E. A., and R. Yakoshi. 1984. Leukocyte Typing. Springer-Verlag, Berlin.
33. Stern, L. J., and D. C. Wiley. 1992. The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide. Cell 68:465.
34. Sloan, V. S., P. Cameron, G. Porter, M. Gammon, M. Amaya, E. Mellins, and D. M. Zaller. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375:802.
35. Busch, R., Z. Reich, D. M. Zaller, V. Sloan, and E. D. Mellins. 1998. Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM. J. Biol. Chem. 273:27557.
36. Gorga, J. C., P. J. Knudsen, J. A. Foran, J. L. Strominger, and S. J. Burakoff. 1986. Immunochemically purified DR antigens in liposomes stimulate xenogeneic cytolytic T cells in secondary in vitro cultures. Cell. Immunol. 103:160.
37. Schafer, P. H., J. M. Green, S. Malapati, L. Gu, and S. K. Pierce. 1996. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes. J. Immunol. 157:5487.
38. Sanderson, F., M. J. Kleijmeer, A. Kelly, D. Verwoerd, A. Tulp, J. J. Neefjes, H. J. Geuze, and J. Trowsdale. 1994. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science 266:1566.
39. Mellins, E., B. Arp, D. Singh, B. Carreno, L. Smith, A. H. Johnson, and D. Pious. 1990. Point mutations define positions in HLA-DR3 molecules that affect antigen presentation. Proc. Natl. Acad. Sci. USA 87:4785.
40. Fling, S. P., B. Arp, and D. Pious. 1994. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 368:554.
41. Morris, P., J. Shaman, M. Attaya, M. Amaya, S. Goodman, C. Bergman, J. J. Monaco, and E. Mellins. 1994. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 368:551.
42. Mellins, E., L. Smith, B. Arp, T. Cotner, E. Celis, and D. Pious. 1990. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 343:71.
43. Verreck, F. A., C. Vermeulen, A. V. Poel, P. Jorritsma, R. Amons, J. E. Coligan, J. W. Drijfhout, and F. Koning. 1996. The generation of SDS-stable HLA DR dimers is independent of efficient peptide binding. Int. Immunol. 8:397.
44. Natarajan, S. K., L. J. Stern, and S. Sadegh-Nasseri. 1999. Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. J. Immunol. 162:3463.
45. Ettinger, R. A., A. W. Liu, G. T. Nepom, and W. W. Kwok. 2000. β57-Asp plays an essential role in the unique SDS stability of HLA-DQA1*0102/DQB1*0602 αβ protein dimer, the class II MHC allele associated with protection from insulin-dependent diabetes mellitus. J. Immunol. 165:3232.
46. Stratikos, E., L. Mosyak, D. M. Zaller, and D. C. Wiley. 2002. Identification of the lateral interaction surfaces of human histocompatibility leukocyte antigen (HLA)-DM with HLA-DR1 by formation of tethered complexes that present enhanced HLA-DM catalysis. J. Exp. Med. 196:173.
47. Belmares, M. P., R. Busch, K. W. Wucherpfennig, H. M. McConnell, and E. D. Mellins. 2002. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J. Immunol. 169:5109.
48. Kropshofer, H., S. O. Arndt, G. Moldenhauer, G. J. Hämmerling, and A. B. Vogt. 1997. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 6:293.
49. Denzin, L. K., C. Hammond, and P. Cresswell. 1996. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J. Exp. Med. 184:2153.
50. Guerra, C. B., R. Busch, R. C. Doebele, W. Liu, T. Sawada, W. W. Kwok, M. D. Chang, and E. D. Mellins. 1998. Novel glycosylation of HLA-DRα disrupts antigen presentation without altering endosomal localization. J. Immunol. 160:4289.
51. Zarutskie, J. A., R. Busch, Z. Zavala-Ruiz, M. Rushe, E. D. Mellins, and L. J. Stem. 2001. The kinetic basis of peptide exchange catalysis by HLA-DM. Proc. Natl. Acad. Sci. USA 98:12450.
52. Bischof, F., W. Wienhold, C. Wirblich, G. Malcherek, O. Zevering, A. M. Kruisbeek, and A. Melms. 2001. Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes. Proc. Natl. Acad. Sci. USA 98:12168.
53. Lombardi, G., L. Barber, S. Sidhu, J. R. Batchelor, and R. I. Lechler. 1991. The specificity of alloreactive T cells is determined by MHC polymorphisms which contact the T cell receptor and which influence peptide binding. Int. Immunol. 3:769.
54. Geluk, A., K. E. van Meijgaarden, A. A. Janson, J. W. Drijfhout, R. H. Meloen, R. R. de Vries, and T. H. Ottenhoff. 1992. Functional analysis of DR17(DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. J. Immunol. 149:2864.
55. Robinson, J., M. J. Waller, P. Parham, J. G. Bodmer, and S. G. Marsh. 2001. IMGT/HLA Database: a sequence database for the human major histocompatibility complex. Nucleic Acids Res. 29:210.
56. Martinsohn, J. T., A. B. Sousa, L. A. Guethlein, and J. C. Howard. 1999. The gene conversion hypothesis of MHC evolution: a review, Immunogenetics 50: 168.
57. Patil, N. S., A. Pashine, M. P. Belmares, W. Liu, B. Kaneshiro, J. Rabinowitz, H. McConnell, and E. D. Mellins. 2001. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles. J. Immunol. 167:7157.
58. Pious, D., L. Dixon, F. Levine, T. Cotner, and R. Johnson. 1985. HLA class II regulation and structure. Analysis with HLA-DR3 and HLA-DP point mutants. J. Exp. Med. 162:1193.
59. Cotner, T., H. Charbonneau, E. Mellins, and D. Pious. 1989. mRNA abundance, rather than differences in subunit assembly, determine differential expression of HLA-DRβ1 and -DRβ3 molecules. J. Biol. Chem. 264:11107.
60. Mellins, E., S. Kempin, L. Smith, T. Monji, and D. Pious. 1991. A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex. J. Exp. Med. 174:1607.
61. Levine, F., H. Erlich, B. Mach, R. Leach, R. White, and D. Pious. 1985. Deletion mapping of HLA and chromosome 6p genes. Proc. Natl. Acad. Sci. USA 82:3741.